-
Mashup Score: 1FDA grants accelerated approval to tarlatamab-dlle for lung cancer - 6 month(s) ago
On May 16, 2024, the FDA granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive stage small cell lung cancer.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0FDA grants accelerated approval to tarlatamab-dlle for lung cancer - 6 month(s) ago
On May 16, 2024, the FDA granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive stage small cell lung cancer.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17FDA grants accelerated approval to tarlatamab-dlle for lung cancer - 6 month(s) ago
On May 16, 2024, the FDA granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive stage small cell lung cancer.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 39FDA grants accelerated approval to tarlatamab-dlle for lung cancer - 6 month(s) ago
On May 16, 2024, the FDA granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive stage small cell lung cancer.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 138
Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCL C) who had not progressed following concurrent chemoradiotherapy (cCRT) compared to placebo after cCRT. Small cell lung cancer (SCLC) is a highly aggressive form of lung
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
🔥🚨@OncoAlert Hot Off the Press BIG NEWS Press Release by @AstraZeneca #ADRIATIC phase 3 trial of #Durvalumab vs #Placebo after concurrent chemoradiotherapy in pts with limited-stage #SmallCell #LungCancer met dual primary endpoints of ⬆️#OS & ⬆️#PFS 👇🏼 https://t.co/DAEapPYsZ7 https://t.co/gjqs85Q90W
-
-
Mashup Score: 138
Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCL C) who had not progressed following concurrent chemoradiotherapy (cCRT) compared to placebo after cCRT. Small cell lung cancer (SCLC) is a highly aggressive form of lung
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
🔥🚨@OncoAlert Hot Off the Press BIG NEWS Press Release by @AstraZeneca #ADRIATIC phase 3 trial of #Durvalumab vs #Placebo after concurrent chemoradiotherapy in pts with limited-stage #SmallCell #LungCancer met dual primary endpoints of ⬆️#OS & ⬆️#PFS 👇🏼 https://t.co/DAEapPYsZ7 https://t.co/gjqs85Q90W
-
-
Mashup Score: 1833rd Annual Mayo Clinic Hematology/Oncology Reviews 2024 | Mayo Clinic School of Continuous Professional Development - 8 month(s) ago
July 25 – 27, 2024 – The Ritz-Carlton Amelia Island – Amelia Island, Florida This course offers Live (in-person) and Livestream (virtual) attendance options. Mayo Clinic’s 33rd Annual Hematology/Oncology Reviews 2024 in Amelia Island, Florida is a comprehensive review of hematology/oncology that focuses on the application of new clinical and research advancements and
Source: ce.mayo.eduCategories: General Medicine News, Hem/OncsTweet-
🚨Announcing the 33rd annual @MayoClinic Florida #Hematology/#Oncology Reviews at Amelia Island Ritz-Carlton (July 2024). Comprehensive conference @MayoCancerCare that focuses on application of new clinical & research advancements over the last year. 👇🏼 https://t.co/bk1zXqkxtO https://t.co/89LZ3FEFxL
-
-
Mashup Score: 69Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3 - 8 month(s) ago
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See complete disclaimer in Appendix 1 and Appendix 2 for more. Updates are published regularly and can be found at https://ascopubs.org/nsclc-non-da-living-guideline. PURPOSE To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer (NSCLC) without driver alterations. METHODS This ASCO living guideline
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 58Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3 - 9 month(s) ago
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See complete disclaimer in Appendix 1 and Appendix 2 for more. Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline. PURPOSE To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer with driver alterations. METHODS This ASCO living guideline offers continua
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 58Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3 - 9 month(s) ago
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See complete disclaimer in Appendix 1 and Appendix 2 for more. Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline. PURPOSE To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer with driver alterations. METHODS This ASCO living guideline offers continua
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
🚨🔥@OncoAlert Hot off the press. @US_FDA granted #accelerated approval to: #Tarlatamab-dlle Approval is for #Patients with #ExtensiveStage #SmallCell #LungCancer (ES #SCLC) who had disease progression on or after platinum-based #Chemotherapy. 👇🏼 https://t.co/0flU8AR4AQ https://t.co/FiRDqtfJx6